Treatment of Hemoglobin H Disease — Deletional Form (Three α-Globin Gene Deletion, No Point Mutations)

This protocol covers the management of Haemoglobin H (HbH) disease in its deletional form: deletion of three α-globin genes with no non-deletional α-globin gene mutation present. Accurate subtype identification is essential, as phenotype and management are directly determined by the underlying genetic changes.

Clinical Scenario

Individuals with deletional HbH disease typically have mild anaemia that is often asymptomatic and may go unrecognised until an incidental laboratory finding prompts workup. Distinguishing this subtype — defined by three α-globin gene deletions and the absence of point mutations — from non-deletional forms is important because phenotype and the approach to care differ between subtypes.

Management Approach

Active intervention, when required, centres on episodic red blood cell transfusion under specific clinical circumstances. The full protocol defines the exact thresholds and clinical situations that determine when transfusion is warranted — including considerations beyond routine monitoring.

Full criteria, decision points, and structured regimen available below.

Instant Access to Structured Evidence-Based Regimens

References

Since phenotype is largely determined by underlying genetic changes, it is important to specify the subtype of HbH disease with the terms deletional (deletion of three α-globin genes) and non-deletional (two or three affected α-globin genes, of which one or more have point mutations).
Individuals with deletional HbH disease usually have mild asymptomatic anaemia that remains unsuspected in many cases until an incidental laboratory finding of anaemia prompts diagnostic workup.
In otherwise uncomplicated situations, it is appropriate to observe the patient and transfuse if the haemoglobin drops <60 g/L in younger children, or <65 g/L in adults.
Transfusion may be needed for surgery or other specific indications.

View source ↗